Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Dr. Sarah Balaster Selected as Finalist for Clinical Leadership Award


Dental Care Alliance (DCA) is exceptionally proud to announce that Dr. Sarah Balaster, Chief Dental Officer, Adult Specialty and Hygiene, and DCA Ally since 2017, has been named a 2023 Women in DSO Clinical Leadership Award Finalist.

The Women in DSO Leadership Award recognizes an individual clinical and business leader in the DSO industry each year. As leaders, these powerful women have made a marked difference across our industry, creating new pathways and empowering others to follow.

Dr. Sarah Balaster is an inspiring and demonstrated clinical leader who stands for identifying and removing barriers between patients and care.

Board Certified in periodontology and dental implant surgery, she strives to empower clinicians to improve both their patients’ lives and their clinical practice outcomes. Dr. Balaster continuously works to elevate dental hygiene, dentistry, and oral health care. She is committed to making a difference and truly leads by example in DCA’s newly established Adult Specialty division. She is a prolific scientific writer, speaker, and instructor; and she is a member of the American Academy of Periodontics, American Dental Association, and the Academy of Laser Dentistry.

The winner of the 2023 Clinical Leadership Award will be announced at the second Women in DSO Empower and Grow event on March 9, 2023.

Dental Care Alliance’s mission is to advance the practice of dentistry by partnering with and supporting dental professionals to create a lifetime of healthy smiles. DCA currently supports over 390 allied practices and supports over 900 dentists across 22 states. DCA’s allied practices represent all dental specialties and treat patients under more than 140 brand names.

Share article on social media or email:

Photonamic and Lumeda Enter into Collaboration for a Clinical Study with Photodynamic Therapy (“PDT”) in the Field of Non-Small Cell Lung Cancer (NSCLC)


News Image

Lumeda Inc, a clinical-stage medical technology company focused on improving treatment outcomes of patients with lung cancer, and photonamic GmbH & Co KG, a pharmaceutical company involved in the development of 5-aminolevulinic acid (5-ALA) in various applications as a precursor for the photosensitizer PpIX, today announced their commitment to collaborate on a Phase I-II clinical study to evaluate the safety and efficacy of Photodynamic Therapy (PDT) with 5-ALA as an adjuvant in combination with Immune Checkpoint Inhibitors (ICIs) to prime the immune system in the treatment of lung cancer patients. The collaboration will combine the respective expertise of both companies, where photonamic’s photosensitizing drug Gleolan™(5-ALA) is used in combination with Lumeda’s proprietary DigiLum™ PDT technology, a breakthrough light delivery and dosimetry system. Ulrich Kosciessa, CEO of photonamic said “The photonamic team is excited about the potential for this collaboration to expand the therapeutic indications for Gleolan™, starting with lung cancer.”

Gleolan™ is approved for use in over 40 countries for fluorescence-guided surgery during brain tumor resection. After a comprehensive global assessment of approved and clinical-stage photosensitizers, Lumeda chose Gleolan™ because of its known safety and tolerability profile as well as its tumor selectivity. This combination study using Gleolan™ and DigiLum™ seeks to assess the response of patients with late-stage lung cancer. Lung cancer is one type of cancer for which PDT has demonstrated the potential to offer clinical benefits. As part of the collaboration, photonamic will invest in Lumeda through a convertible note and will supply the clinical trial product through its wholly-owned subsidiary in the USA, NX Development Corp. Inc. Sandy Zinke, Lumeda CEO said, “We believe that the combination of Gleolan™ and DigiLum™ can produce strong clinical results which can in turn lead to broader adoption of PDT in combination with immunotherapy to improve outcomes for lung cancer patients.”

About 5-aminolevulinic acid in PDT:

5-aminolevulinic acid (“5-ALA”) is an endogenous amino acid derivative produced in mitochondria. Aminolevulinic acid is a normal precursor of protoporphyrin IX (PpIX), which is extensively metabolized in cancer cells whereas in combination with iron ions is metabolized to hemoglobin. PpIX is a photosensitizer that can be activated by light of a certain wavelength to produce reactive oxygen species which cause tumor cell death. PDT with 5-ALA is currently being investigated in clinical trials and is not approved for use in clinical practice. 5-ALA is contraindicated in patients with hypersensitivity to 5-ALA or porphyrins or patients with acute/chronic porphyria.

About Lumeda, Inc.:

Lumeda was founded in 2019 and has developed DigiLum™, a breakthrough light delivery and dosimetry system with AI software, designed to make PDT more standardized and efficient to enable broader adoption and treatment of more patients. Lumeda has a close collaboration with the world-renowned Photodynamic Therapy (PDT) Center at Roswell Park Comprehensive Cancer Center in Buffalo, NY. The company has an exclusive global license to two Roswell Park patents that enable the application of intraoperative PDT for patients suffering from lung cancer and pleural malignancies. Lumeda is currently involved in two clinical studies at Roswell Park related to lung cancer and is developing other tools to enable the use of PDT in robotic and endoscopic procedures for additional indications. For more information please go to the Lumeda website at http://www.lumedainc.com or contact Sandy Zinke, Lumeda CEO at sandyz@lumedainc.com.

About photonamic GmbH & Co KG:

photonamic is a German based company involved in the development of 5-ALA in various applications as precursor for the photosensitizer PpIX. As a member of the SBI group with its parent company SBI ALApharma Hong Kong, photonamic has developed 5-ALA for the fluorescence-guided resection of glioblastoma which is marketed as Gliolan®, Gleolan™ or Alabel™ in Europe, United States, Canada, Japan, Australia and Korea. Within the group, photonamic and its affiliated companies in the US, Canada and Japan are diligently extending the development activities with 5-ALA even outside the field of photodynamic application, e.g. immune modulation in infectious diseases, food supplement and cosmetics.

Forward-Looking Information

This press release contains forward-looking statements. Generally, words such ad “may”, “will”, “should”, “could”, “anticipate”, “expect”, “intend”, “estimate”, “plan”, “continue”, and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements.

Share article on social media or email:

CIONCA IP Provides Support for St. Jude Children’s Research and the Tunnel to Towers Foundation


Orange County trademark law firm

CIONCA IP, an intellectual property and trademark law firm in Orange County is pleased to announce that they will be sponsoring and making monthly donations to two charities. The first charity helps the Tunnel to Towers Foundation, and the second is St. Jude Children’s Research Hospital.

Every year, the attorney and team at CIONCA IP donates to various nonprofit organizations who are making a positive impact in local, regional, and nationwide communities. Especially during tough economic times, are challenging times for nonprofits, as products, services and labor costs continue to rise. To be able to advance their missions, support from the business sector, is crucial to be able to serve those in need.

This year, CIONCA IP chose to donate to St. Jude Children’s Research Hospital and another charity, the Tunnel to Towers Foundation, that helps those affected by war or first-responder type of public service. These charities are dedicated to assisting children with health challenges and to helping people to rebuild their lives free from mortgages, respectively.

The CIONCA IP team is dedicated to giving their energy, time, and skills to helping those in need in the communities where they live, work, and play. Corporate social responsibility is woven in the firm’s DNA and has been a key priority for CIONCA IP for many years. According to Marin Cionca, the founder of CIONCA IP, “It is a privilege for our team at CIONCA IP to show our appreciation and support for nonprofits who are changing lives for the better for the most unfortunate in our communities.”

For over a decade, CIONCA IP has been blessed to create a law firm that has become recognized for not only success for clients, but for its corporate social responsibility. “For so long as our intellectual property and trademark law firm continues winning for our clients and their families, we will continue to donate a portion of our profits to charitable and non-profit organizations here in Orange County and beyond.”

About CIONCA IP

CIONCA IP is an Orange County intellectual property law firm founded in 2009 and the firm focuses on intellectual property law, trademarks, patents, IP licensing, and copyrights. The legal experience of the firm’s attorney and staff is deep and extensive, enabling them to offer a full range of IP legal service of trademark and patent protection to businesses of all sizes and in diverse industries. CIONCA IP is dedicated to helping clients by delivering cost-efficient, sensitive flat-fee trademark services.

To learn more about CIONCA IP’s charitable initiatives, you can reach Marin Cionca at 949-334-3036 or email marin@cioncaip.com. Visit CIONCA IP’s official website at https://www.cioncaip.com/ to learn more about the law firm’s services.

###

Share article on social media or email:

Community Health Accreditation Partner Awards QAPIplus Its “CHAP Verified” Status


QAPIplus, the only quality management software (QMS) solution developed exclusively for home health and hospice organizations, announces that it is the first QMS solution to achieve CHAP Verified status.

CHAP Verified status is granted to tools and resources used by community-based care providers that, through rigorous inspection, show no roadblocks to executing the CHAP Standards of Excellence, and innovate to improve the delivery of high quality care. CHAP performed a critical review of QAPIplus and found that it enables organizations to meet the intent of CHAP’s applicable standards.

QAPIplus is the only QMS solution purpose-built for home health and hospice that automates the workflows associated with QAPI, Infection Control and Emergency Management programs for home health and hospice organizations. QAPIplus customers can unlock higher quality and performance while reducing the burden of compliance and quality management on care teams.

“CHAP is honored to recognize QAPIplus as the first quality management software solution to earn the elite status of CHAP verification,” said Daniel Stephens, SVP, Center for Excellence. “The solution provides home health and hospice organizations with the necessary tools to support their QAPI, Infection Control and Emergency Management programs. Going through the rigorous vetting process to ensure that their software solution meets CHAP’s standards of excellence shows that the Leadership Team strongly strives to meet the needs of providers to maintain a high level of quality while being survey-ready at all times.”

“We are thrilled to have QAPIplus verified by CHAP,” said Armine Khudanyan, CEO of Health Forum Plus, the company behind QAPIplus. “Meeting their high standards validates our mission to help home health and hospice organizations maximize their performance so they can make a real difference with their patients, payers and care providers, while streamlining workflows to make quality and compliance easier to manage.”

About QAPIplus

QAPIplus, from Health Forum Plus is the only quality management software solution purpose-built for home health and hospice organizations that unlocks high performance so they can make a real difference for their patients, payers and care providers. QAPIplus streamlines workflows for QAPI, Infection Control, Emergency Management, and other critical quality programs by digitizing the entire process, thereby lowering the cost of compliance, minimizing burden on care teams and empowering a higher level of quality and performance. Founded by a nurse and experienced QAPI consultant, the company also provides extensive clinical guidance as well as resources for in-services and human resource support. For more information, visit http://www.QAPIplus.com or email us at info@qapiplus.com.

About Community Health Accreditation Partner (CHAP)

CHAP is an independent, nonprofit organization accrediting providers of home and community-based care. Founded in 1965, CHAP was first to recognize the need for and value of home and community-based care standards and accreditation. As a Centers for Medicare & Medicaid Services (CMS)–approved accrediting organization, CHAP surveys organizations providing home health, hospice, and home medical equipment services to establish if Medicare Conditions of Participation and DMEPOS Quality Standard are met and recommend certification to CMS. CHAP’s purpose is to partner with organizations nationwide to advance quality in the delivery of care and services in the home and community.

Share article on social media or email:

NACDS Defines “PBM Reform” for Senate Commerce Committee Hearing


We look forward to continuing to work with Congress to stop the manipulation by PBM go-betweens that increases patients’ medication costs, limits patients’ choice of pharmacies, and restricts access to medicines that are right for them.

With increasing bipartisan focus on pharmacy benefit managers’ (PBM) tactics that harm patients and the pharmacies that serve them, the National Association of Chain Drug Stores (NACDS) is defining the solutions for comprehensive reform.

“We look forward to continuing to work with Congress to stop the manipulation by PBM go-betweens that increases patients’ medication costs, limits patients’ choice of pharmacies, and restricts access to medicines that are right for them,” wrote NACDS President and CEO Steven C. Anderson in a statement for today’s U.S. Senate Committee on Commerce, Science, & Transportation hearing, “Bringing Transparency and Accountability to Pharmacy Benefit Managers.”

NACDS detailed “policy recommendations to increase transparency and ensure comprehensive reform of harmful PBM practices”:

Help to Preserve Patient Access to Pharmacies by Addressing PBMs’ Retroactive Pharmacy Fees


  • Retroactive Direct and Indirect Remuneration Fees (DIR Fees)/Claw Backs – Policymakers should prohibit payers or PBMs from retroactively reducing and/or denying a processed pharmacy drug claim payment, and obligate them to offer predictable and transparent pharmacy reimbursement to better protect pharmacies as viable and reliable access points for care.

Provide Fair and Adequate Payment for Pharmacy Patient Care Services

  • Reasonable Reimbursement and Rate Floor – To help maintain robust public access to pharmacies, policymakers should adopt a reimbursement rate floor that requires PBMs to use comprehensive reimbursement models that are no less than the true cost to purchase and dispense prescription drugs.
  • Standardized Performance Measures – Policymakers should standardize PBMs’ performance measures for pharmacies to help set achievable goals for pharmacies before signing a contract, and to promote harmonization in the healthcare system and improvements in health outcomes.

Protect Patient Choice of Pharmacies

  • Specialty Pharmacy – Policymakers should establish appropriate standards for defining and categorizing specialty drugs to ensure comprehensive and pragmatic patient care and access. Policymakers should prohibit PBMs from steering patients to only specialty pharmacies, including those owned by the PBMs, for their prescription needs.
  • Mail Order – Policymakers should support patient choice and access by enacting laws to prohibit PBMs from requiring or steering patients to use mail-order pharmacies.
  • Any Willing Pharmacy – Policymakers should require PBMs and plans to include any pharmacies in their networks if the pharmacy is willing to accept the terms and conditions established by the PBM. This will help to maximize patient outcomes and cost savings.

Enforce Laws to Stop PBM Manipulation and Protect Pharmacies and Patients

  • Audits – Policymakers should support fair pharmacy audit practices to ensure timely patient care delivery at community pharmacies and bring efficiency, transparency, and standardization to the PBM audit process.
  • Oversight Authority – Policymakers should establish and enforce laws already on the books to regulate harmful PBM reimbursement practices that may harm patients and the healthcare system as we know it, especially at the pharmacy counter, and empower state regulators to do the same to enforce PBM transparency and fair and adequate pharmacy reimbursement.

More information about the implications of current “pharmaceutical benefit manipulation” is available in a 100-second explainer video and a two-page document by NACDS.

Share article on social media or email:

Top Beverly Hills Plastic Surgeon, Dr. John Anastasatos, Celebrates the Grand Opening and Press Event for Los Angeles Plastic Surgery in Athens, Greece


News Image

“By my expansion there I wish to make Athens an international destination of advanced aesthetic surgery just like Beverly Hills. Already half of my patients there came from other countries including the US for the specific purpose of having surgery by me,” says Dr. Anastasatos.

Beverly Hills plastic surgeon, Dr. John Anastasatos and the Athens Medical Group recently hosted a celebration for the grand opening of the Los Angeles Plastic Surgery location in Athens, Greece. Bringing Beverly Hills to Athens with Dr. Anastasatos’ practice at the Advanced Aesthetic Plastic Surgery Center, this cosmopolitan city now provides an innovative, sophisticated and safe destination for cutting-edge procedures, with the goal of turning it into an international destination for patients to enjoy the best in advanced plastic surgery. Recently recognized by the Lux Insider as one of the “World’s Top 10 Plastic Surgeons,” Dr. John Anastasatos has owned a very successful plastic surgery practice in California, Los Angeles Plastic Surgery, and now operates his own plastic surgery clinic in Athens, Greece. He is a true leader in his field with a clientele who travel near and far to benefit from his skill and talent. An honors graduate of Brown University, Dr. Anastasatos trained in general and plastic surgery at Columbia University in NYC and additionally in plastic surgery and microsurgery at the University of Alabama- Birmingham. He has gained a reputation for his ability to create amazing, natural results for his patients, including facelifts, advanced breast augmentations, body correction procedures and non-surgical treatments. Many of his plastic surgeries are performed endoscopically and under local anesthesia, which results in a lower risk to his patients and a shorter healing time.

“My family roots are in Greece, and I am thrilled to offer beautiful plastic surgical results for patients at our clinic location in Athens,” Dr. John Anastasatos. “By my expansion there I wish to make Athens an international destination of advanced aesthetic surgery just like Beverly Hills. Already half of my patients there came from other countries including the US for the specific purpose of having surgery by me.”

More about Dr. John Anastasatos:

At Los Angeles Plastic Surgery, Dr. John Anastasatos is highly regarded for his skill in cosmetic, reconstructive and revision procedures, including gold-standard facelifts, breast augmentations, body lift procedures, liposuction and non-surgical treatments. Dr. Anastasatos has received many accolades, including being one of America’s Most Honored Doctors – Top 5%, and “US News and World Report” declared him one of the top plastic surgeons in the U.S. Castle Connolly also has consistently recognized him as one of the top plastic surgeons, and The United States Congress honored Dr. Anastasatos for his contributions in plastic surgery and charity service. Other awards Dr. Anastasatos has received include “Who is Who International ” in September 2022, “Most Eminent man of Plastic Surgery,” and Rankipedia named Dr. Anastasatos Top 1% Plastic Surgeon in the US for 2021.

To schedule a consultation or for more information on his practice locations in Beverly Hills, CA, please call (310) 888-4048, or visit his website http://www.LosAngelesPlasticSurgery.com. To schedule a consultation or for more information about his practice located at Palas Kefalari, Kolokotroni, 23 Kifisia, 145 62 in Athens Greece, please call +30 210 682 4021 or visit https://www.drjohnanastasatos.gr/.

Share article on social media or email:

Episcopal Relief & Development Partners with the ACT Alliance to Support Earthquake Survivors in Syria


Photo Courtesy of the ACT Alliance

“We have been partnering with the ACT Alliance for over 20 years,” said Abagail Nelson, Executive Vice President and Chief Strategy Officer, Episcopal Relief & Development. “This has allowed us to respond quickly to those who need assistance due to this devastating earthquake.”

Episcopal Relief & Development is partnering with Action by Churches Together (ACT Alliance) to provide emergency relief to people affected by the 7.8- and 7.5-magnitude earthquakes in Türkiye (Turkey) and Syria. Working through the Middle East Council of Churches (MECC) and other local organizations, the ACT Alliance is providing shelter, supplies and support to families and local hospitals.

More than 39,000 people have been killed in Türkiye (Turkey) and Syria following the earthquakes and thousands of buildings have been destroyed or deemed unusable. Cold weather combined with rain and snow has complicated conditions for those without shelter. In Syria, an estimated 10.9 million people have been affected and up to 5.3 million may have lost their homes.

MECC is responding in Syria by sheltering 10,000 families in open-air or structurally sound facilities; providing survivors with hot meals, blankets, medicine and trauma support; supplying body bags and other necessities to hospitals; and helping children return to school to bring more stability. Additionally, local organizations are providing winterization and hygiene kits, cash transfers and emotional support for people in Syria.

“We have been partnering with the ACT Alliance for over 20 years,” said Abagail Nelson, Executive Vice President and Chief Strategy Officer, Episcopal Relief & Development. “Most recently, we’ve worked together to support families affected by the war in Syria. Partners had pre-positioned supplies in the area. This has allowed us to respond quickly to those who need assistance due to this devastating earthquake.”

Episcopal Relief & Development continues to talk with partners working in Türkiye (Turkey) and Syria to assess the medium- and long-term needs.

Please continue to pray for those who have been affected by the earthquake. Donations to the Türkiye (Turkey)-Syria Earthquake Response Fund will help the organization to continue to respond to communities impacted by this disaster.

ABOUT EPISCOPAL RELIEF & DEVELOPMENT

For over 80 years, Episcopal Relief & Development has been working together with supporters and partners for lasting change around the world. Each year the organization facilitates healthier, more fulfilling lives for more than 3 million people struggling with hunger, poverty, disaster and disease. Inspired by Jesus’ words in Matthew 25, Episcopal Relief & Development leverages the expertise and resources of Anglican and other partners to deliver measurable and sustainable change in three signature program areas: Women, Children and Climate.

Share article on social media or email:

The Healthcare Technology Report’s Top 25 Women Leaders in Medical Devices of 2023


The Healthcare Technology Report is pleased to announce The Top 25 Women Leaders in Medical Devices of 2023. Technology is advancing at a rapid pace across industries, and perhaps nowhere is that more true than in the medical device market. In fact, according to Fortune Business Insights, the global market is projected to grow from roughly $495 billion in 2022 to nearly $719 billion by 2029 at a CAGR of 5.5%. There is intense competition in the market, and the women on this year’s list and the companies they represent have found success innovating across a range of specialties, from insulin management systems to regenerative technologies, electrotherapy, and wireless surgical solutions.

Some of the distinguished leaders on this year’s list include Tania Saison, SVP and CCO/CRO of Edwards Lifesciences, who oversees the company’s Global Integrity Program, which establishes a comprehensive framework for ensuring compliance with applicable laws, regulations, and standards of conduct. Meanwhile, Jennifer Ernst, CEO of Tivic Health, built her company from founding to IPO in 5 years and put an award-winning medical device into market within 3 years. And Manisha Shah-Bugaj, COO of Activ Surgical, oversees the ongoing development and commercialization of the company’s products, including ActivSight™ Intelligent Light, which aims to provide enhanced visualization and real-time, on-demand surgical insights in the operating room.

The awardees on this year’s list lead from a range of positions, from President and CEO to SVP, EVP, and COO. What they have in common is their dedication to innovation in the medical device space, bringing revolutionary new devices to market and improving the lives of patients and clinicians alike. Please join us in celebrating The Top 25 Women Leaders in Medical Devices of 2023.

Tania Saison (Edwards Lifesciences), Simona Serban (Fresenius Medical Care), Aviva McPherron (NuVasive), Elizabeth Sebern McCombs (BD), Niamh Pellegrini (Nevro), Lena Hagman (XVIVO), Jennifer Ernst (Tivic Health), Manisha Shah-Bugaj (Activ Surgical), Abba Lucsok (Zynex Medical), Sreelakshmi Kolli (Align Technology), Deborah Gordon (Insulet), Suzanne Winter (Accuray), Sandra Hirsch (Zyris, Inc.), Tavia Walsh (Pulse Technologies), Jennifer Honeycutt (Danaher), Pooja Pathak (LumiraDx), Kelli Howell (Alphatec Spine), Alison Burdett (The Surgical Company), Rhonda Robb (Cardiovascular Systems, Inc.), Jessica Lynch (DentalMonitoring), Rebecca Lin (Potrero Medical), Kristie West (Orchid Orthopedic Solutions), Liz Hammack (Pristine Surgical), Dina Dubey (Teleflex).

The full article can be read at https://thehealthcaretechnologyreport.com/

About The Healthcare Technology Report

The Healthcare Technology Report provides market research and insights, business news, investment activity updates, and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers, and media professionals highly knowledgeable on healthcare technology and the various companies, executives, and investors that make up the sector.

Share article on social media or email:

5 Ways to save on everyday healthcare items and avoid losing money to the March 15 flexible spending account (FSA) grace period deadline


According to proprietary data from Health-E Commerce, 37% of people with a grace period deadline still forfeit funds because they aren’t aware of their deadline or they do not know how they can use their funds.

An important deadline is drawing near for many of the more than 30 million Americans who are enrolled in flexible spending accounts (FSAs): The March 15 grace period deadline. This optional deadline extension offered by employers gives individuals and families who had a December 31, 2022 FSA deadline until March 15, 2023 to continue to spend down funds from their 2022 benefits plan year. Unfortunately, according to proprietary data from Health-E Commerce, 37% of people with a grace period deadline still forfeit funds because they aren’t aware of their deadline or they do not know how they can use their funds.

What is the FSA grace period? The grace period is an optional FSA deadline extension that employers can offer to help employees avoid forfeiting FSA funds by giving them extra time to spend down funds from the previous plan year. For benefits plans that run on a calendar year, the FSA grace period deadline is March 15. However, for benefit plans that do not renew on January 1, the grace period is 2.5 months after the end of their plan year. For example, if the plan year ends on March 31, the grace period deadline will be June 15.

As the parent brand to FSA Store – the first and largest online marketplace that sells only items that are eligible for purchase with FSA funds – Health-E Commerce shares the following five ways that consumers can save on everyday healthcare items, reduce their taxable income, and avoid losing FSA money to a missed deadline.

Additional FSA extension options to know. In addition to the grace period, consumers should be aware of two additional extensions that employers may offer. It’s important to note that all FSA extensions are optional and determined by the employer.

  • Carryover. The FSA carryover allowed those who had the extension to carry over up to $570 in unused FSA funds from 2022 to 2023. For carryovers in 2023, that amount increases to $610. Note that those with an FSA carryover feature do not have a grace period, and vice versa, as only one of the two is allowed.
  • Runout Period. The FSA run-out period gives account holders up to three months following the last day of the plan year to continue to submit receipts and claims for qualified expenses that were incurred during the FSA plan year. For FSA participants with a plan year that ended on December 31, 2022, the last day of their FSA run-out period would be on March 31, 2023. These account holders have until March 31, 2023 to submit claims for expenses incurred by or before December 31, 2022.

To learn what’s eligible and spend down remaining funds, explore the searchable eligibility list at FSA Store, and use interactive calculators that help budget and plan future expenses. FSA Store also offers Deadline Alerts, which help consumers stay in front of important dates, so they never miss a deadline again.

###

About Health-E Commerce

Health-E Commerce is the parent brand to FSA Store, HSA Store and WellDeservedHealth, a family of online marketplaces that serve the 70+ million consumers enrolled in pre-tax health and wellness accounts. The company also created Caring Mill, a popular private-label line of health products that benefits Children’s Health Fund and enables customers to make a donation with each purchase. Since 2010, the Health-E Commerce brands have led7 the direct-to-consumer e-commerce market for exclusively pre-tax health and wellness benefits. Health-E Commerce plays an essential role in expanding product eligibility for important new categories within the list of eligible medical expenses.

Share article on social media or email:

Labroots to Host 6th Annual Drug Discovery & Development Online Event, February 22, 2023


Drug Discovery & Development, February 22, 2023

Labroots, the leading scientific social networking website offering premier, interactive virtual events and webinars, is hosting its Drug Discovery & Development virtual event on February 22, 2023. The 6th annual free event in the Drug Discovery & Development Virtual Event Series, is a dynamic reputable forum bringing together thousands of innovative research scholars, clinicians and scientists across leading, medical, industry, and academic professions from around the world.

The one-day informative agenda will feature over fifteen educational and sponsored presentations featuring the latest scientific findings while showcasing distinguished speakers in the field including, a keynote delivery by Professor Kevin Pfleger, PhD, Director of Biomedical and Health Innovation at The University of Western Australia explaining how molecular pharmacology approaches can be used to profile potential drug candidates prior to preclinical development.

“My laboratory has spent the last 20 years developing a molecular pharmacology profiling platform that is able to monitor various facets of receptor binding, signalling and trafficking in live cells and in real-time,” said Professor Kevin Pfleger, Director of Biomedical and Health Innovation at The University of Western Australia and Head of Molecular Endocrinology and Pharmacology at the Harry Perkins Institute of Medical Research. “This has uncovered novel pharmacology that underpins drug development by Dimerix and RAGE Biotech, with Dimerix progressing well beyond preclinical development into Phase 3 clinical trials. I’m excited to highlight these capabilities through Labroots’ unique platform.”

Drug Discovery & Development 2023 promises to deliver on its commitment of bringing emerging topics to the forefront of the scientific community such as Improved Models in Drug Discovery and Preclinical Development, New Methods in PK/PD and Pharmacogenomics, and Biomarker Applications in Clinical Development.

These sessions (not limited to) will cover characterization of anti-HER2 antibodies using advanced flow cytometry and BLI label-free detection and get pipetting right – tips and tricks for accurate and reproducible results – both talks with live Q&A and sponsored by Sartorius; and using single B technology to develop lead antibody molecules on GPCR targets with live Q&A, sponsored by DIMA Biotech. Spanning the day, additional presentations on demand for immediate viewing when the event is live explore avoiding In Vivo study pitfalls, current use of GPCR pharmacogenomics in clinical practice, innovative biomarker spatial analysis for comprehensive tissue immunophenotyping, PDX/PDO models for precision cancer medicine beyond mutations naming just a few and much more, you won’t want to miss!

Produced on Labroots’ robust platform, this online event allows participants to connect seamlessly across desktop and mobile devices, delivering a one-stop complete educational experience. The interactive environment includes a lobby equipped with a leaderboard and gamification, an auditorium featuring live-streaming video webcasts with live attendee chats during scheduled presentations, an exhibit hall to interact with sponsors highlighting contributions in the field, a poster hall to explore data and engage in live chat conversations complete with a poster competition giving your research a competitive edge, and a networking lounge to encourage collaborations with colleagues. By participating, there is a potential to earn up to 1 P.A.C.E. Continuing Education credit per presentation for a maximum of 30 credits.

To register for the event, click here. Remember to use the hashtag #LRdrug to follow the conversation and connect with other members of the global Drug Discovery & Development community!

Follow @DrugDiscoveryLR on Twitter and @DrugDiscoveryandDevelopment on Facebook to connect with our specialist Drug Discovery & Development writers and stay up to date with the latest Trending News in Drug Discovery & Development. You can now also join our Drug Discovery, Development, & Therapeutics professional networking group on LinkedIn!

About Labroots

Labroots is the leading scientific social networking website, and primary source for scientific trending news and premier educational virtual events and webinars and more. Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks and communities. Founded in 2008, Labroots emphasizes digital innovation in scientific collaboration and learning. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, Labroots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events. Labroots offers more than ever with Chati, a flexible, highly scalable event platform that allows for the creation of unique, effective, and memorable virtual events.

Share article on social media or email: